OncoMatch/Clinical Trials/NCT06446713
PIRATES: Image-guided Hyper-fractioned Dose-escalation With Proton Therapy for Head and Neck Cancer
Is NCT06446713 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies non-drug interventions for head and neck cancer.
In this study the safety \& feasibility of image-guided mid-treatment hyper-fractioned dose-escalation with proton therapy will be assessed for the treatment of locally advanced HPV-negative squamous cell oropharyngeal cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: CDKN2A wild-type
Negative for p16
Disease stage
Required: Stage III, IV
Prior therapy
Cannot have received: definitive resection
Exception: incisional or excisional biopsies
underwent definitive resection of their primary tumor or nodal disease, except for incisional or excisional biopsies
Cannot have received: radiation therapy
received radiation therapy in the head and neck area in the past
Lab requirements
Kidney function
estimated gfr < 60 ml/min/1.73 m2 or any contraindications to gadolinium-based contrast agents
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06446713 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior definitive resection, radiation therapy disqualifies patients from enrollment.
Does this trial require CDKN2A?
Yes, CDKN2A wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages